🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the face of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Data and Global Access

As per findings published in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the typical regimen, which uses an injection and a pill. The trial enrolled hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in many regions with limited resources.

Clinicians directly involved have shared hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for public health efforts. This is considered crucial to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.